People & Promotions

Gradalis Inc.

Joseph M. Limber

President and CEO

DALLAS—Gradalis Inc. announced this week theappointment of Joseph M. Limber as president and CEO. Limber, whom the companydescribes as "a pharmaceutical veteran," brings more than 30 years oflife-science management experience to a position in which he will "utilize hisvast pharmaceutical business acumen and commercial expertise as the companyfocuses on developing safe, personalized and effective therapeutics in cancerand other indications." Prior to joining Gradalis, Limber served as president,CEO and director of Prometheus Laboratories Inc., a specialty company focusedon developing and commercializing diagnostics and pharmaceutical products forpersonalized clinical management of patients in the gastroenterology andoncology therapeutic areas. During Limber's 10-year tenure, Prometheusdeveloped and launched several successful diagnostics products, acquired andlicensed multiple pharmaceutical products, experienced approximately 30-percentcompounded annual growth rate and 30-percent operating margins, with revenuegrowth from approximately $69 million in 2003 to well over a half-billiondollars, culminating in the successful acquisition of Prometheus by NestleHealth Science in July of 2011.

EnVivo Pharmaceuticals

Deborah Dunsire, M.D.

President and CEO

WATERTOWN, Mass.—Mid-July saw EnVivoPharmaceuticals, a company dedicated to developing a broad range of noveltherapies for central nervous system diseases, announced the appointment of Dr.Deborah Dunsire as president, CEO and a member of the board of directors. Dunsire,who had been president and CEO of Millennium: The Takeda Oncology Company from2005 to 2013, brings more than 25 years of scientific, clinical, operationaland commercial experience, and leadership in the biological and pharmaceuticalindustry. During her time at Millennium, she reportedly transformed the companyinto a biotechnology industry leader "by focusing R&D, driving thedevelopment pipeline, fostering a culture of employee engagement and increasingthe commercial mindset across the organization to enhance the commercialsuccess of marketed products."

BioOhio

John F. Lewis Jr.

President and CEO

COLUMBUS, Ohio—BioOhio's board of trustees thisweek appointed John F. Lewis Jr.

as the new president and CEO of the state'sbioscience trade association, succeeding Dr. Anthony J. Dennis, who announcedhis retirement in April. Lewis has served in numerous capacities at BioOhio,most recently as chief operating officer and interim president. Lewis also brings significant globalexperience to the position. Accompanied by two Ohio governors, Lewis has ledbioscience-focused trade missions to Germany, Japan, China, Taiwan, France andIsrael. In concert with key BioOhio partners, Lewis helped to market Ohiocompanies internationally as well as to attract global companies to locate newoperations in Ohio.

Visterra Inc.

Brian J.G. Pereira, M.D.

President and CEO

CAMBRIDGE, Mass.—Visterra, a developer of novelmedicines to prevent and treat infectious and other major diseases, announced inmid-July the appointment of Dr. Brian Pereira as president, CEO and member ofthe board of director, taking on the leadership role "at a time when Visterrais advancing its product candidates into human clinical trials for infectiousdiseases that impact global health," the company notes. Prior to joiningVisterra, Pereira served as the president and CEO of AMAG Pharmaceuticals Inc. from2006 to 2011 and as its president from 2005 to 2006. At AMAG, Pereira "playedthe leadership role in rapidly creating value," Visterra says, in part by raisingfour financing rounds at increasing valuations and building the clinicaldevelopment, manufacturing, supply-chain, commercial and financialinfrastructure for AMAG's iron therapy product for anemia.

BioClinica Inc.

David S. Herron

Executive Vice President and President of Imaging Core Lab Division

NEWTOWN, Pa.— David S. Herron in mid-July became executivevice president at BioClinica, a global provider of clinical trial managementservices, and president of its Imaging Core Lab Division. In these roles, Herronis responsible for the global strategic planning and operations of BioClinica'smedical imaging management solutions, which include software and services forthe electronic transfer, management and independent review of medical imagesfor clinical trials. Prior to joining BioClinica, Herron served as an executive-in-residencewith DW Healthcare Partners, a private equity firm focused on healthcareopportunities.

Rho

Richard Koenig

Vice President of Operations

CHAPEL HILL, N.C.—On July 15, Richard Koenig joinedRho as vice president of operations, bringing almost 30 years of operationsmanagement and clinical development experience, with his most recent position havingbeen vice president of operations for ClinStar LLC, located in Durham, N.C. Inhis position with Rho, Koenig will lead a growing team of researchprofessionals, including principal investigators, clinical research associates,data managers, biostatisticians, statistical programmers, project and programmanagers, among others.

Aesica

Bashir Hansraj

Global Technical Director

NEWCASTLE, U.K.—Global development and contractmanufacturing organization Aesica had appointed a global technical director,Bashir Hansraj, who will be responsible for developing leading technical centersacross the entire international Aesica network from API and drug productdevelopment sites right through to finished product manufacturing andpackaging. Hansraj brings more than 30 years of experience in thepharmaceutical industry, having held senior management R&D positions withinPfizer, Johnson & Johnson and most recently at Catalent, where he was headof research and development.

Epizyme Inc.

Jason P. Rhodes
President

CAMBRIDGE, Mass.—Epizyme, a clinical-stagebiopharmaceutical company creating innovative personalized therapeutics forpatients with genetically defined cancers, announced in early July that JasonP. Rhodes, executive vice president and chief financial officer, has been elevatedto president of Epizyme. Rhodes will continue to be chief financial officer aswell and report to Dr. Robert J. Gould, the company's CEO. Prior to joiningEpizyme in March 2010, he had served since 2007 as vice president of businessdevelopment at Alnylam Pharmaceuticals Inc., where he reportedly drove theestablishment and management of several key strategic alliances and contributedto the growth of the business in many ways.

Novasep

Michel Spagnol

President and CEO

POMPEY, France—Novasep, a leading provider ofpurification-based manufacturing solutions for life-sciences molecules, announcedin late June the appointment of Michel

Spagnol as president and CEO of thecompany, succeeding Patrick Glaser who, after three years at Novasep in France,has decided to return to the United States. Spagnol joins Novasep from Shasun,where he was president and chief technology officer, and Novasep calls him "aproven business leader with core expertise in leading contract manufacturing ofactive pharmaceutical ingredients. More broadly, he has strong experience inusing and developing innovative technologies to address the needs of customersin fine chemicals and life sciences fields."

OsoBio

Kathleen Larese

Director of Laboratories

ALBUQUERQUE, N.M.—As of late June, Kathleen Laresebecame director of laboratories for OsoBio and, as part of the company'squality control department, the microbiology and chemistry laboratories thatLarese now directs are responsible for environmental monitoring, analyticalmethod development, and testing all incoming raw materials, components, andin-process and finished products involved in the company's cGMP sterilemanufacturing operations. Larese brings to OsoBio more than 10 years ofmanagement experience in laboratory operations responsible for regulatorycompliance, project documentation, quality assurance, inventory management andwaste disposal. Most recently, she was senior technical staff member at SandiaNational Laboratories, where, as OsoBio notes, "she used her black beltcertification in Lean and Six Sigma to reduce waste and optimize operations."

Oxford BioTherapeutics

Bryan G. Morton

Chairman

OXFORD, U.K.—Oxford BioTherapeutics, a globalbiotechnology company developing first-in-class, antibody-based cancermedicines to fulfill unmet patient needs, announced in June the appointment ofBryan G. Morton as the company's new non-executive chairman.

Morton brings over 30 years' experience as asuccessful entrepreneur and senior manager in the pharmaceutical industry, andhe was previously CEO of EUSA Pharma, a global speciality oncology company,which was acquired by Jazz Pharmaceuticals in 2012 for $700 million.

Southern Research Institute

Arthur J. Tipton, Ph.D.

President and CEO

BIRMINGHAM, Ala.—Mid-June saw Southern ResearchInstitute announce that Dr. Arthur J. Tipton had been selected by its board ofdirectors to serve as president and CEO of Southern Research effective July 8,2013. Tipton replaces Dr. John A. SecristIII, who served as president and CEO of Southern Research Institute for sevenyears. Secrist announced his retirement earlier this year after 34 years of overallservice at Southern Research. Tipton previously served as senior vice presidentand general manager of Evonik–Birmingham Laboratories in Birmingham, Ala.During his career, he has helped lead the growth of three pharmaceutical/biotechcompanies and launched four commercial products. He holds 31 U.S. patents withnumerous foreign equivalents, and he has more than 70 publications,presentations and invited lectures to his credit.